Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464373 | 0.85 | TSHR (0.32) | TAAR1 | |
| SCHEMBL1172152 | 0.84 | TAAR1 (0.39) | TAAR1 | |
| SCHEMBL1171876 | 0.79 | HTR1A (0.34) | TAAR1 | |
| SCHEMBL1172224 | 0.78 | BACE1 (0.32) | BACE1 | |
| SCHEMBL1172201 | 0.75 | BACE1 (0.33) | BACE1 | |
| SCHEMBL1171987 | 0.73 | BACE1 (0.36) | BACE1 | |
| SCHEMBL1172386 | 0.71 | SLC6A3 (0.38) | BACE1 | |
| SCHEMBL15488573 | 0.69 | TAAR1 (0.39) | TAAR1 | |
| SCHEMBL4468713 | 0.69 | HTT (0.39) | BACE1 | |
| SCHEMBL4462368 | 0.69 | HTR5A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| EP-1981856-A2 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | EPHB4, EPHB1, EPHB3 | BACE1 3399/4885TAAR1 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.